Management of low-risk patients with thyroid carcinoma and detectable thyroglobulin on T4 after thyroidectomy and ablation with iodine-131

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 51, Issue 1, 2007, Pages 99-103

  Rosário, Pedro Weslley Souza ^a,c   Borges, Michelle A R ^a   Costa, Graciela B C ^a   Rezende, Leonardo L ^b   Padrão, Eduardo L ^b   Barroso, Álvaro L ^b   Purisch, Saulo ^a  

^a Endocrinology Service   (Brazil)

^b Nuclear Medicine Service   (Brazil)

^c Centro de Estudos e Pesquisa da Clinica de Endocrinologia e Metabologia CEPCEM   (Brazil)

Author keywords

Detectable Tg on T4; Radioiodine; Thyroid cancer

Indexed keywords

RADIOACTIVE IODINE; THYROGLOBULIN; THYROXINE; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; EVALUATION; FEMALE; HUMAN; LUNG TUMOR; LYMPH NODE; MALE; METASTASIS; MIDDLE AGED; PREDICTION AND FORECASTING; THYROID TUMOR; THYROIDECTOMY;

ADOLESCENT; ADULT; AGED; CARCINOMA; FEMALE; HUMANS; IODINE RADIOISOTOPES; LUNG NEOPLASMS; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; THYROXINE; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 34247127065     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302007000100016     Document Type: Article

References (18)

1. Pacini F. Follow-up of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2002;29:S492-6.
2. 131I scanning. J Clin Endocrinol Metab 2002;87:1486-9.
3. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 2000;85:175-8.
4. 131I whole-body scan after initial treatment of low-risk differentiated thyroid cancer. Thyroid 2004;14:301-6.
5. Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003;89:1638-44.
6. Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 2004;150:105-12.
7. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. The American Thyroid Association Guidelines Taskforce. Guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109-42.
8. American Joint Committee on Cancer Thyroid 2002. In: Greene FL, Page BL, Fleming ID, Fritz A, Balch CM, Haller BG, et al, eds. AJCC cancer staging handbook. 6th ed. Chapter 8. New York: Springer, 2002. pp. 89-98.
9. Rosário PW, de Faria S, Bicalho L, Alves MF, Borges MA, Purisch S, et al. Ultrasonographic differentiation between metastatic and benign lymph nodes in patients with papillary thyroid carcinoma. J Ultrasound Med 2005;24:1385-9.
10. Gruning T, Tiepolt C, Zophel K, Bredow J, Kropp J, Franke WG. Retinoic acid for redifferentiation of thyroid cancer. Does it hold its promise? Eur J Endocrinol 2003;148:395-402.
11. Baudin E, Do Cao C, Cailleux AF, Leboulleux S, Travagli JP, Schlumberger M. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab 2003;88:1107-11.
12. 131I therapy for elevated thyroglobulin levels. Thyroid 1997;7:273-6.
13. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 2003;88:3668-73.
14. David A, Blotta A, Rossi R, Zatelli MC, Bondanelli M, Roti E, et al. Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma. Thyroid 2005;15:267-73.
15. Giovanni V, Arianna LG, Antonio C, Francesco F, Michele K, Giovanni S, et al. The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: experience from a large patient cohort in a single centre. Clin Endocrinol (Oxf) 2002;56:247-52.
16. Torlontano M, Attard M, Crocetti U, Tumino S, Bruno R, Costante G, et al. Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab 2004;89:3402-7.
17. Rosário PW, Guimarães VC, Maia FF, Fagundes TA, Purisch S, Padrão EL, et al. Thyroglobulin before ablation and correlation with posttreatment scanning. Laryngoscope 2005;115:264-7.
18. Mazzaferri EL. Empirically treating high serum thyroglobulin levels. J Nucl Med 2005;46:1079-88.